Epigenetic Regulation of the Clinical Signs of Friedreich’s Disease

被引：0

作者：

Nuzhny E.P. ^{[1
]}

Abramycheva N.Y. ^{[1
]}

Nikolaeva N.S. ^{[1
]}

Ershova M.V. ^{[1
]}

Klyushnikov S.A. ^{[1
]}

Illarioshkin S.N. ^{[1
]}

Fedotova E.Y. ^{[1
]}

机构：

[1] Neurology Science Center, Moscow

来源：

Neuroscience and Behavioral Physiology | 2020年 / 50卷 / 8期

关键词：

DNA methylation; epigenetics; expansion of trinucleotide repeats; Friedreich’s disease; phenotypic heterogeneity;

D O I：

10.1007/s11055-020-00998-9

中图分类号：

学科分类号：

摘要：

Objectives. To study the methylation profile of the FXN gene and its influence on the formation of the clinical presentation of Friedreich’s disease (FD). Materials and methods. The promoter area and intron 1 of the FXN gene up to the GAA expansion (UP-GAA) and after the GAA expansion (DOWN-GAA) regions were studied in 17 patients with FD, with analysis of a total of 45 CpG sites. Results. Studies of genetic-epigenetic interactions identified correlations between the extent of methylation of a series of CpG sites in the UP-GAA and DOWN-GAA and the number of GAA repeats in both expanded alleles of the FXN gene in patients with FD. We also found a link between methylation and the presence of the extraneural signs of FD: cardiomyopathy was more likely to be present when the CpG site of the promoter region was hypermethylated, while impairments to carbohydrate metabolism were more common in hypomethylation of CpG sites in the DOWN-GAA area. Conclusions. The data obtained here provide evidence that epigenetic modifications of the FXN gene make a significant contribution to forming the clinical picture of FD. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.

引用

页码：1000 / 1004

页数：4

共 23 条

[1]

Illarioshkin S.N., Rudenskaya G.E., Ivanova-Smolenskaya I.A., Et al., Inherited Ataxias and Paraplegias, (2006)

[2]

Burk K., Friedreich ataxia: Current status and future prospects, Cerebellum Ataxias, 4, 4. Ecollection, (2017)

[3]

Ershova M.V., Illarioshkin S.N., Molecular base of Friedreich’s ataxia, Zh. Nevrol. Psikhiatr., 103, 2, pp. 61-67, (2003)

[4]

Faraj S.E., Roman E.A., Aran M., Et al., The alteration of the C-terminal region of human frataxin distorts its structural dynamics and function, FEBS J., 281, 15, pp. 3397-3419, (2014)

[5]

Heidari M.M., Houshmand M., Hosseinkhani S., Et al., Complex I and ATP content deficiency in lymphocytes from Friedreich’s ataxia, Can. J. Neurol. Sci., 36, 1, pp. 26-31, (2009)

[6]

Parkinson M.H., Boesch S., Nachbauer W., Et al., Clinical features of Friedreich’s ataxia: Classical and atypical phenotypes, J. Neurochem., 126, pp. 103-117, (2013)

[7]

Weidemann F., Stork S., Liu D., Et al., Cardiomyopathy of Friedreich Ataxia, J. Neurochem., 126, pp. 88-93, (2013)

[8]

Weidemann F., Rummey C., Bijnens B., Et al., The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms, Circulation, 125, pp. 1626-1634, (2012)

[9]

Fomicheva E.I., Myasnikov R.P., Seliverstov Y.A., Et al., Cardiomyopathy in Friedreich’s ataxia: clinical signs and diagnosis of complications, Ross. Kardiol. Zh., 10, 150, pp. 100-106, (2017)

[10]

McCormick A., Farmer J., Perlman S., Et al., Impact of diabetes in the Friedreich ataxia clinical outcome measures study, Ann. Clin. Transl. Neurol., 4, 9, pp. 622-631, (2017)

← 1 2 3 →